LEADER 00953nam--2200349---450-
001 990001499220203316
005 20050422104831.0
035   $a000149922
035   $aUSA01000149922
035   $a(ALEPH)000149922USA01
035   $a000149922
100   $a20040312d1962----km-y0itay0103----ba
101 0 $aita
102   $aIT
105   $a||||||||001yy
200 1 $a<<I>> conquistadores$fGiotto Dainelli
210   $aTorino$cUTET$d1962
215   $aV, 389 p.$d26 cm
410  0$12001
454  1$12001
461  1$1001-------$12001
700  1$aDAINELLI,$bGiotto$075309
801  0$aIT$bsalbc$gISBD
912   $a990001499220203316
951   $aIII.1. Coll. 6/ 7(I A coll 13/9)$b12383 L.M.$cI A coll
959   $aBK
969   $aUMA
979   $aSIAV5$b10$c20040312$lUSA01$h1134
979   $aPATRY$b90$c20040406$lUSA01$h1744
979   $aCOPAT1$b90$c20050422$lUSA01$h1048
996   $aConquistadores$9675591
997   $aUNISA

LEADER 01236nam  2200373Ia 450 
001 9910699379103321
005 20230902162200.0
035   $a(CKB)5470000002402122
035   $a(OCoLC)499058546
035   $a(EXLCZ)995470000002402122
100   $a20100115d2008      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $ehypertension indication, drug labeling for cardiovascular outcome claims
210  1$aSilver Spring, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[2008]
215   $a1 online resource (7 pages)
300   $a"Labeling."
300   $a"March 2008."
320   $aIncludes bibliographical references (page 7).
517   $aGuidance for industry 
606   $aHypertension
606   $aDrugs$xLabeling
615  0$aHypertension.
615  0$aDrugs$xLabeling.
712 02$aCenter for Drug Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699379103321
996   $aGuidance for industry$93434577
997   $aUNINA